NOTE TO ALL - Look what Lef says about I3C/DIM and auto-immune:
http://www.lef.org/newsletter/2010/...htm?source=search&key=endometrial cancer cure
I3C was found to be superior to 80 other compounds, including tamoxifen, for anticancer potential. Indoles, which down-regulate estrogen receptors, have been proposed as promising agents in the treatment and prevention of cancer and
autoimmune diseases such as multiple sclerosis, arthritis, and lupus.
Replacement of all the chemically altered estrogen drugs, such as tamoxifen, with a new generation of chemically altered indole drugs that fit in the aryl-hydrocarbon (Ah) receptor and regulate estrogen indirectly may prove beneficial to cancer patients (Bitonti et al. 1999). An I3C tetrameric derivative (chemically derived) is currently a novel lead inhibitor of breast cancer cell growth, considered a new, promising therapeutic agent for both ER+ and ER- breast cancer (Brandi et al. 2003).
A summary of studies shows that indole-3-carbinol (I3C) can:
Stop human cancer cells from growing (54-61%) and provoke the cells to self-destruct (apoptosis) (Telang et al. 1997)
Inhibit human breast cancer cells (MCF7) from growing by as much as 90% in vitro (Ricci et al. 1999)
Inhibit the growth of estrogen-receptor-positive breast cancer cells by 90%, compared to tamoxifen's 60%, by stopping the cell cycle (Cover et al. 1999)
Prevent chemically induced breast cancer in rodents by 70-96%. Prevent other types of cancer, including aflatoxin-induced liver cancer, leukemia, and colon cancer (Grubbs et al. 1995)
Inhibit free radicals, particularly those that cause the oxidation of fat (Shertzer et al. 1988)
Stop the synthesis of DNA by about 50% in estrogen-receptor-negative cells, whereas tamoxifen had no significant effect (Cover et al. 1998)
Restore p21 and other proteins that act as checkpoints during the synthesis of a new cancer cell. Tamoxifen has no effect on p21 (Cover et al. 1998)
Virtually eliminate DNA damage and cancer prior to exposure to cancer-causing chemicals (in animals fed I3C) (Grubbs et al. 1995)
Reduce DNA damage in breast cells by 91% (Devanaboyina et al. 1997)
Life Extension Magazine July, 2010 issue now online
http://www.lef.org/magazine/mag2006...source=search&key=endometrial cancer cure I3C
Numerous cell culture, animal, and human studies have demonstrated I3Cs safety and tolerability,20-22 along with its targeted ability to suppress cancer growth and induce programmed cell death in a variety of tumors, including those associated with breast, prostate, endometrial, leukemia, and colon cancers.1